Trial reportActa oto-laryngologica2015
Herbal drug BNO 1016 is safe and effective in the treatment of acute viral rhinosinusitis.
Trial report in Acta oto-laryngologica, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Current state of research on the clinical benefits of herbal medicines for non-life-threatening ailments.Frontiers in pharmacology · 2023Pooled it
- Guideline
- Review
- Effects of Essential Oils in the Treatment of Acute Rhinosinusitis: A Systematic Review.Laryngoscope investigative otolaryngology · 2025Review
- Herbal Medicine in Acute and Chronic Sinusitis; Still a Cinderella?Current allergy and asthma reports · 2025Review
- Holistic care in mild upper respiratory tract infections (MURTIs): an approach to individualized care management.Drugs in context · 2025Review
- Exploring the association between phytopharmaceutical use and antibiotic prescriptions in upper respiratory infections: results from a German cohort study evaluating the impact of naturopathy qualifications of general practitioners using routine data.Frontiers in medicine · 2024Article
- Therapeutic Effects of Vitamins and Nutritional Supplements on Sinusitis: A Narrative Review.Nutrition and metabolic insights · 2024Review
- Changes in the Prescription of Antibiotics and Phytopharmaceuticals in Children Treated for Acute Upper and Lower Respiratory Tract Infections in Pediatric Practices in Germany in 2013, 2018, and 2022.Antibiotics (Basel, Switzerland) · 2023Article
- The treatment of mild upper respiratory tract infections - a position paper with recommendations for best practice.Drugs in context · 2023Review
- Contribution of Symptomatic, Herbal Treatment Options to Antibiotic Stewardship and Microbiotic Health.Antibiotics (Basel, Switzerland) · 2022Review
- A Herbal Formula in the Therapy of Acute Postviral Rhinosinusitis.Turkish archives of otorhinolaryngology · 2021Article
- Herbal dry extract BNO 1011 improves clinical and mucociliary parameters in a rabbit model of chronic rhinosinusitis.International forum of allergy & rhinology · 2019Article
- The role of bitter and sweet taste receptors in upper airway innate immunity: Recent advances and future directions.World journal of otorhinolaryngology - head and neck surgery · 2018Review
- Overuse of diagnostic tools and medications in acute rhinosinusitis in Spain: a population-based study (the PROSINUS study).BMJ open · 2018Observational
- Promising approaches for the treatment and prevention of viral respiratory illnesses.The Journal of allergy and clinical immunology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
conclusionDaily intake of 480 mg of BNO 1016 for 15 days is an effective treatment in acute viral rhinosinusitis.
objectivesThe pooled efficacy data of two similar randomized placebo-controlled clinical trials were analyzed. Safety was evaluated on the basis of the individual trials.
methodsThe efficacy analysis was based on 589 patients. Treatment was performed orally with either 3 × 160 mg BNO 1016 (n = 294) or 3 × placebo (n = 295) for 15 days. In both trials patients underwent five visits to the investigational sites. Symptoms were evaluated according to the EPOS 2012 guideline. Ultrasonography was used to confirm the diagnosis at onset of treatment and the remission of symptoms at the last visit. Efficacy was evaluated by the investigator as the mean major symptom score (MSS) at the end of treatment (visit 5, day 14). Patients reported symptoms and social/emotional consequences of rhinosinusitis using a quality of life questionnaire (SNOT-20 GAV).
resultsMSS improved during the treatment period by a mean of 10.02 ± 1.61 score points to 2.47 ± 2.55 for BNO 1016 and of 9.87 ± 1.52 to 3.63 ± 3.63 for placebo. Differences between treatment groups at end of therapy (1.16 ± 3.14 score points; p < 0.0001) and patient-assessed quality of life (p = 0.0015) were statistically significant in favor of BNO 1016.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.